CN115916200A - 炎症性肠病的治疗 - Google Patents

炎症性肠病的治疗 Download PDF

Info

Publication number
CN115916200A
CN115916200A CN202180043624.XA CN202180043624A CN115916200A CN 115916200 A CN115916200 A CN 115916200A CN 202180043624 A CN202180043624 A CN 202180043624A CN 115916200 A CN115916200 A CN 115916200A
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutical composition
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043624.XA
Other languages
English (en)
Chinese (zh)
Inventor
M·H·约翰森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aquilion Ltd
Original Assignee
Aquilion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aquilion Ltd filed Critical Aquilion Ltd
Publication of CN115916200A publication Critical patent/CN115916200A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202180043624.XA 2020-04-30 2021-04-30 炎症性肠病的治疗 Pending CN115916200A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2006390.5A GB202006390D0 (en) 2020-04-30 2020-04-30 Novel treatments
GB2006390.5 2020-04-30
PCT/EP2021/061462 WO2021219879A1 (en) 2020-04-30 2021-04-30 Treatments of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
CN115916200A true CN115916200A (zh) 2023-04-04

Family

ID=71080611

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180043624.XA Pending CN115916200A (zh) 2020-04-30 2021-04-30 炎症性肠病的治疗
CN202180044567.7A Active CN115768429B (zh) 2020-04-30 2021-04-30 用于治疗炎症性肠病的5-氯-4-羟基-1-甲基-2-氧代-n-苯基-喹啉-3-甲酰胺钾盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180044567.7A Active CN115768429B (zh) 2020-04-30 2021-04-30 用于治疗炎症性肠病的5-氯-4-羟基-1-甲基-2-氧代-n-苯基-喹啉-3-甲酰胺钾盐

Country Status (9)

Country Link
US (2) US20230167064A1 (enExample)
EP (2) EP4142725A1 (enExample)
JP (2) JP2023524519A (enExample)
KR (2) KR20230018386A (enExample)
CN (2) CN115916200A (enExample)
AU (2) AU2021266154A1 (enExample)
CA (2) CA3177000A1 (enExample)
GB (2) GB202006390D0 (enExample)
WO (2) WO2021219879A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
JP2023527782A (ja) * 2020-05-21 2023-06-30 ステムシナジー セラピューティクス， インク． Ｎｏｔｃｈ阻害剤及びその使用
CN115120727B (zh) * 2022-06-16 2024-02-23 甘肃农业大学 S100a9抑制剂在制备防治c型产气荚膜梭菌感染性腹泻药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024195A1 (en) * 1994-03-10 1995-09-14 Pharmacia & Upjohn Ab New use of quinoline-3-carboxamide compounds
US20110027219A1 (en) * 2009-07-30 2011-02-03 Teva Pharmaceutical Industries, Ltd. Treatment of Crohn's disease with laquinimod
US20120010238A1 (en) * 2010-07-09 2012-01-12 Victor Piryatinsky Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
WO2012050500A1 (en) * 2010-10-14 2012-04-19 Lars Pettersson 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
EP2061440A2 (en) * 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
JP5934202B2 (ja) * 2010-07-09 2016-06-15 テバ ファーマシューティカル インダストリーズ リミティド ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用
US9200046B2 (en) * 2011-06-29 2015-12-01 Cornell University Reporter system for high throughput screening of compounds and uses thereof
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024195A1 (en) * 1994-03-10 1995-09-14 Pharmacia & Upjohn Ab New use of quinoline-3-carboxamide compounds
US20110027219A1 (en) * 2009-07-30 2011-02-03 Teva Pharmaceutical Industries, Ltd. Treatment of Crohn's disease with laquinimod
US20120010238A1 (en) * 2010-07-09 2012-01-12 Victor Piryatinsky Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
WO2012050500A1 (en) * 2010-10-14 2012-04-19 Lars Pettersson 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
US20130203703A1 (en) * 2010-10-14 2013-08-08 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KEISUKE FURUMATSU 等: "A Role of the Aryl Hydrocarbon Receptor in Attenuation of Colitis", DIG DIS SCI, 15 March 2011 (2011-03-15), pages 2532 - 2544, XP019949811, DOI: 10.1007/s10620-011-1643-9 *
SELMA MAHIOUT 等: "In vitro toxicity and in silico docking analysis of two novel selective AHreceptor modulators", TOXICOLOGY IN VITRO, 13 June 2018 (2018-06-13), pages 178 - 188 *

Also Published As

Publication number Publication date
WO2021219881A1 (en) 2021-11-04
US20230167064A1 (en) 2023-06-01
KR20230018386A (ko) 2023-02-07
CN115768429B (zh) 2024-02-09
GB202006390D0 (en) 2020-06-17
AU2021266154A1 (en) 2023-01-05
AU2021262514A1 (en) 2023-01-05
KR20230024892A (ko) 2023-02-21
EP4142725A1 (en) 2023-03-08
GB2605894A (en) 2022-10-19
CN115768429A (zh) 2023-03-07
JP2023524519A (ja) 2023-06-12
WO2021219879A1 (en) 2021-11-04
JP2023524518A (ja) 2023-06-12
EP4142724A1 (en) 2023-03-08
US20230202982A1 (en) 2023-06-29
GB202207709D0 (en) 2022-07-06
GB2605894B (en) 2023-06-14
JP7702427B2 (ja) 2025-07-03
CA3177000A1 (en) 2021-11-04
CA3176994A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
AU2006233165B2 (en) Antineoplastic combinations
CN101905023B (zh) 有效的医药使用方法及与副作用发生的防御相关的方法
AU2002330994A1 (en) Antineoplastic combinations
KR20230024892A (ko) 염증성 장 질환의 치료
WO2018204713A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
US8501738B2 (en) Substituted triazolo-pyridazine derivatives
US12048689B2 (en) Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4
WO2007123511A2 (en) Dosing regimens for the treatment of cancer
CN117736193B (zh) 一种氘代稠环化合物及其制备方法与用途
EP1973887B1 (en) Aza heterocyclics for the treatment of malaria or aids
JP2010536827A (ja) ある種の炎症性障害の治療に有用なカルボニルアミノ誘導体
US11103489B2 (en) Drug for preventing or treating inflammatory bowel disease
FR2823975A1 (fr) Nouvelle utilisation de pyridoindolone
JP5118648B2 (ja) 疾患の処置および予防のための組成物および方法
JPS63284170A (ja) 新規グアニジノメチル−チオフエンカルボン酸誘導体
JP2009167137A (ja) フェニルアルカン酸誘導体を含有する医薬
HK1061204B (en) Antineoplastic combinations
AU2006331357A1 (en) Compositions and methods for synthesizing novel heterocyclic therapeutics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination